27
Participants
Start Date
August 4, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
February 28, 2030
Pembrolizumab 25 MG/ML [Keytruda]
"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
ACTIVE_NOT_RECRUITING
Centre Georges François Leclerc, Dijon
ACTIVE_NOT_RECRUITING
Centre Hospitalier Régional Universitaire de Besançon, Besançon
RECRUITING
Oncopole Claudius Regaud - IUCT Oncopole, Toulouse
ACTIVE_NOT_RECRUITING
Institut Bergonié, Bordeaux
WITHDRAWN
ICM Val d'Aurelle, Montpellier
RECRUITING
ICO - Paul Papin, Angers
ACTIVE_NOT_RECRUITING
Centre Hospitalier Universitaire d'Angers, Angers
ACTIVE_NOT_RECRUITING
Centre Oscar Lambret, Lille
RECRUITING
ICANS - Institut de cancérologie Strasbourg Europe, Strasbourg
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
CHU de Limoges - Hôpital Dupuytren, Limoges
RECRUITING
Gustave Roussy, Villejuif
Merck Sharp & Dohme LLC
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER